To report our methods for expression and purification of α7 nicotinic acetylcholine receptor (α7-nAChR), a ligand-gated pentameric ion channel and an important drug target. α7-nAChRs of 10 ...

today announced an update on the company’s α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD (known as Merck & Co., Inc., Rahway NJ ...

The α7 nicotinic acetylcholine receptor (α7nAChR) binds the amyloid-β peptide (Aβ) with high affinity (Wang et al., 2000), and has been implicated in Aβ internalization, stimulation of tau ...

Written up as a novel, the relationship between Aβ and the α7 nicotinic acetylcholine receptor (α7 nAChR) has the makings of a bestseller—promise, peril, and mystery. Though earlier pages have ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210 US $ ...

After striking out for years to characterize the structure of a key nicotinic acetylcholine receptor called α7, Noviello and Hibbs got a major boost in 2016 after UTSW purchased equipment for ...

Activation of the α7 nicotinic acetylcholine receptor may be therapeutically useful against acute lung injury by suppressing expression of pro-inflammatory genes.

Currently, the main treatments for Alzheimer’s disease are drugs that increase levels of acetylcholine in the brain. The University of Bristol paper, published today in Cell Reports, describes the ...

More information: Spyridon Papapetropoulos et al, BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder, NEJM Evidence (2024). DOI: 10.1056/EVIDoa2400380 Journal ...